Suppr超能文献

相似文献

2
Immunoglobulin-binding protein-based affinity chromatography in bispecific antibody purification: Functions beyond product capture.
Protein Expr Purif. 2021 Dec;188:105976. doi: 10.1016/j.pep.2021.105976. Epub 2021 Sep 16.
4
Effects of molecule hydrophobicity and structural flexibility of appended bispecific antibody on Protein A chromatography.
J Chromatogr A. 2024 Aug 30;1731:465206. doi: 10.1016/j.chroma.2024.465206. Epub 2024 Jul 22.
6
Solvent modulated linear pH gradient elution for the purification of conventional and bispecific antibodies: Modeling and application.
J Chromatogr A. 2015 Oct 30;1418:119-129. doi: 10.1016/j.chroma.2015.09.053. Epub 2015 Sep 25.
7
8
Exploration of overloaded cation exchange chromatography for monoclonal antibody purification.
J Chromatogr A. 2011 Sep 28;1218(39):6943-52. doi: 10.1016/j.chroma.2011.08.008. Epub 2011 Aug 12.
10
Efficient bispecific monoclonal antibody purification using gradient thiophilic affinity chromatography.
J Chromatogr B Biomed Sci Appl. 1998 Sep 4;714(2):161-70. doi: 10.1016/s0378-4347(98)00180-7.

引用本文的文献

1
A two-column process for bispecific antibody purification based on MabSelect VL resin's strong byproduct removal capability.
J Biol Methods. 2024 Dec 12;12(1):e99010045. doi: 10.14440/jbm.2025.0106. eCollection 2025.
2
Rapid affinity-based purification of multi-specific antibodies using Kappa Select and Protein L.
MAbs. 2025 Dec;17(1):2483272. doi: 10.1080/19420862.2025.2483272. Epub 2025 Mar 28.
4
Calcium chloride and arginine show diametrically opposite effects on antibody elution in Protein A and Protein L chromatography.
J Biol Methods. 2024 Jul 10;11(2):e99010016. doi: 10.14440/jbm.2024.0006. eCollection 2024.
5
Current trends and challenges in the downstream purification of bispecific antibodies.
Antib Ther. 2021 May 7;4(2):73-88. doi: 10.1093/abt/tbab007. eCollection 2021 Apr.
6
Modelling of pH-dependence to develop a strategy for stabilising mAbs at acidic steps in production.
Comput Struct Biotechnol J. 2020 Mar 10;18:897-905. doi: 10.1016/j.csbj.2020.03.002. eCollection 2020.

本文引用的文献

2
Bispecific antibodies: design, therapy, perspectives.
Drug Des Devel Ther. 2018 Jan 22;12:195-208. doi: 10.2147/DDDT.S151282. eCollection 2018.
3
Evolving trends in mAb production processes.
Bioeng Transl Med. 2017 Apr 3;2(1):58-69. doi: 10.1002/btm2.10061. eCollection 2017 Mar.
4
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors.
Sci Transl Med. 2017 Oct 4;9(410). doi: 10.1126/scitranslmed.aal4291.
5
Bispecific T cell engager (BiTE®) antibody constructs can mediate bystander tumor cell killing.
PLoS One. 2017 Aug 24;12(8):e0183390. doi: 10.1371/journal.pone.0183390. eCollection 2017.
6
Affibody molecules as engineered protein drugs.
Exp Mol Med. 2017 Mar 24;49(3):e306. doi: 10.1038/emm.2017.35.
7
In vitro-engineered non-antibody protein therapeutics.
Protein Cell. 2018 Jan;9(1):3-14. doi: 10.1007/s13238-017-0386-6. Epub 2017 Mar 7.
8
The making of bispecific antibodies.
MAbs. 2017 Feb/Mar;9(2):182-212. doi: 10.1080/19420862.2016.1268307.
9
10
A Novel Bispecific Antibody against Human CD3 and Ephrin Receptor A10 for Breast Cancer Therapy.
PLoS One. 2015 Dec 17;10(12):e0144712. doi: 10.1371/journal.pone.0144712. eCollection 2015.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验